HIV type 1 zidovudine (ZDV) resistance in blood and uterine cervical secretions of pregnant women

AIDS Research and Human Retroviruses

Volumn 22, Issue 9, 2006, Pages 870-873

  Frenkel, Lisa M ^a,b   McKernan, Jennifer ^b   Dinh, Phil V ^a   Goldman, Deborah ^a   Hitti, Jane ^a   Watts, D Heather ^a,d   Cooper, Ellen R ^c   Dragavon, Joan ^a   Coombs, Robert W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD; CODON; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; UTERINE CERVIX MUCUS; VIRUS MUTANT; VIRUS RESISTANCE; VIRUS TYPING;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CERVIX MUCUS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA-DIRECTED DNA POLYMERASE; ZIDOVUDINE;

EID: 33751032856     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.870     Document Type: Article

References (15)

1. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331(18):1173-1180.
2. Cooper ER, Charurat M, Mofenson L, et al.: Combination anti-retroviral strategics for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29(5):484-494.
3. Jackson JB, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362(9387):859-868.
4. Lallemant M, Jourdain G, Le Coeur S, et al.: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351 (3):217-228.
5. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351(3):229-240.
6. Philpott S, Burger H, Tsoukas C, et al.: Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: Compartmentalization and intrapatient recombination. J Virol 2005;79(1):353-363.
7. Iversen AK, Learn GH, Skinhøj P, Mullins JI, McMichael AJ, and Rambaut A: Preferential detection of HIV subtype C over subtype A in cervical cells from a dually-infected woman. AIDS 2005;19:990-993.
8. Panther LA, Tucker L, Xu C, Tuomala RE, Mullins JI, and Anderson DJ: Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in perinatal HIV-1 transmission. J Infect Dis 2000;181(2):555-563.
9. Si-Mohamed A, Kazatchkine MD, Heard I, et al.: Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000;182(1):112-122.
10. Edelstein RE, Nickerson EA, Tobe VO, Manns-Arcuino LA, and Frenkel LM: Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 1998;36(2):569-572.
11. Newstein M, Losikoff P, Caliendo A, et al.: Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract. J Acquir Immune Defic Syndr 2005;38(3):364-366.
12. Eastman PS, Shapiro DE, Coombs RW, et al.: Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177(3):557-564.
13. Boucher CA, O'Sullivan E, Mulder JW, et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-110.
14. Ellis GM, Mahalanabis M, Beck IA, et al.: Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclcar cells and plasma. J Clin Microbiol 2004;42(8):3670-3674.
15. Bardeguez AD, Shapiro DE, Mofenson LM, et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003;32(2):170-181.